Plixorafenib for BRAF-mutated glioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new targeted drug called plixorafenib, either alone or combined with another drug (retifanlimab), for people with a BRAF-mutated brain tumor. The goal is to see if the drug can reach the brain and control the tumor, while checking for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a glioma (a type of brain tumor) with a specific BRAF-V600E mutation
- You have already been treated with a BRAF or MEK inhibitor
- You are 18 years or older and able to take care of yourself (Karnofsky score 70 or higher)
- You haven't had radiation in the last 12 weeks or chemotherapy in the last 4-8 weeks (depending on type)
- Your blood counts and organ function are in a safe range (like hemoglobin, kidney and liver function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests a drug called Belvarafenib for people with brain tumors that have a BRAF gene change (mutation). The drug targets this specific change to try to shrink or control the tumor. It is for patients whose brain tumor has come back or hasn't responded to other treatments.
Hear when a new BRAF V600E Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.